TROP2 Expression in Sebaceous and Sweat Gland Carcinoma
Sebaceous carcinoma and sweat gland carcinoma (malignant tumors with apocrine and eccrine differentiation) are rare malignant skin adnexal tumors that differentiate toward sebaceous gland and eccrine and apocrine glands, respectively. Owing to the rarity of these carcinomas, standard treatments for...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/3/607 |
| _version_ | 1797486943298125824 |
|---|---|
| author | Takamichi Ito Hiroki Hashimoto Yuka Tanaka Keiko Tanegashima Maho Murata Toshio Ichiki Takeshi Iwasaki Yoshinao Oda Yumiko Kaku-Ito |
| author_facet | Takamichi Ito Hiroki Hashimoto Yuka Tanaka Keiko Tanegashima Maho Murata Toshio Ichiki Takeshi Iwasaki Yoshinao Oda Yumiko Kaku-Ito |
| author_sort | Takamichi Ito |
| collection | DOAJ |
| description | Sebaceous carcinoma and sweat gland carcinoma (malignant tumors with apocrine and eccrine differentiation) are rare malignant skin adnexal tumors that differentiate toward sebaceous gland and eccrine and apocrine glands, respectively. Owing to the rarity of these carcinomas, standard treatments for advanced disease have not been established. Because the prognosis of patients with systemic metastasis is poor, a new treatment for these diseases is eagerly desired. Trophoblast cell surface antigen 2 (TROP2) and sacituzumab govitecan, an antibody–drug conjugate of TROP2, have attracted attention in the treatment of various solid tumors. In the current study, we immunohistochemically investigated TROP2 expression in 14 sebaceous carcinoma and 18 sweat gland carcinoma samples and found strong and relatively homogeneous TROP2 staining in both cancer types. The mean Histoscore, a semi-quantitative scoring ranging from 0 (negative) to 300, was 265.5 in sebaceous carcinoma and 260.0 in sweat gland carcinoma. These observations directly suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with TROP2-targeted antibody–drug conjugates such as sacituzumab govitecan. |
| first_indexed | 2024-03-09T23:41:31Z |
| format | Article |
| id | doaj.art-0d56e97d6fd84f58872078f57d7cc61d |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-09T23:41:31Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-0d56e97d6fd84f58872078f57d7cc61d2023-11-23T16:51:10ZengMDPI AGJournal of Clinical Medicine2077-03832022-01-0111360710.3390/jcm11030607TROP2 Expression in Sebaceous and Sweat Gland CarcinomaTakamichi Ito0Hiroki Hashimoto1Yuka Tanaka2Keiko Tanegashima3Maho Murata4Toshio Ichiki5Takeshi Iwasaki6Yoshinao Oda7Yumiko Kaku-Ito8Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, JapanSebaceous carcinoma and sweat gland carcinoma (malignant tumors with apocrine and eccrine differentiation) are rare malignant skin adnexal tumors that differentiate toward sebaceous gland and eccrine and apocrine glands, respectively. Owing to the rarity of these carcinomas, standard treatments for advanced disease have not been established. Because the prognosis of patients with systemic metastasis is poor, a new treatment for these diseases is eagerly desired. Trophoblast cell surface antigen 2 (TROP2) and sacituzumab govitecan, an antibody–drug conjugate of TROP2, have attracted attention in the treatment of various solid tumors. In the current study, we immunohistochemically investigated TROP2 expression in 14 sebaceous carcinoma and 18 sweat gland carcinoma samples and found strong and relatively homogeneous TROP2 staining in both cancer types. The mean Histoscore, a semi-quantitative scoring ranging from 0 (negative) to 300, was 265.5 in sebaceous carcinoma and 260.0 in sweat gland carcinoma. These observations directly suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with TROP2-targeted antibody–drug conjugates such as sacituzumab govitecan.https://www.mdpi.com/2077-0383/11/3/607trophoblast cell surface antigen 2 (TROP2)skin cancersebaceous carcinomasweat gland carcinomasacituzumab govitecantargeted therapy |
| spellingShingle | Takamichi Ito Hiroki Hashimoto Yuka Tanaka Keiko Tanegashima Maho Murata Toshio Ichiki Takeshi Iwasaki Yoshinao Oda Yumiko Kaku-Ito TROP2 Expression in Sebaceous and Sweat Gland Carcinoma Journal of Clinical Medicine trophoblast cell surface antigen 2 (TROP2) skin cancer sebaceous carcinoma sweat gland carcinoma sacituzumab govitecan targeted therapy |
| title | TROP2 Expression in Sebaceous and Sweat Gland Carcinoma |
| title_full | TROP2 Expression in Sebaceous and Sweat Gland Carcinoma |
| title_fullStr | TROP2 Expression in Sebaceous and Sweat Gland Carcinoma |
| title_full_unstemmed | TROP2 Expression in Sebaceous and Sweat Gland Carcinoma |
| title_short | TROP2 Expression in Sebaceous and Sweat Gland Carcinoma |
| title_sort | trop2 expression in sebaceous and sweat gland carcinoma |
| topic | trophoblast cell surface antigen 2 (TROP2) skin cancer sebaceous carcinoma sweat gland carcinoma sacituzumab govitecan targeted therapy |
| url | https://www.mdpi.com/2077-0383/11/3/607 |
| work_keys_str_mv | AT takamichiito trop2expressioninsebaceousandsweatglandcarcinoma AT hirokihashimoto trop2expressioninsebaceousandsweatglandcarcinoma AT yukatanaka trop2expressioninsebaceousandsweatglandcarcinoma AT keikotanegashima trop2expressioninsebaceousandsweatglandcarcinoma AT mahomurata trop2expressioninsebaceousandsweatglandcarcinoma AT toshioichiki trop2expressioninsebaceousandsweatglandcarcinoma AT takeshiiwasaki trop2expressioninsebaceousandsweatglandcarcinoma AT yoshinaooda trop2expressioninsebaceousandsweatglandcarcinoma AT yumikokakuito trop2expressioninsebaceousandsweatglandcarcinoma |